Q1 EPS Estimates for Scholar Rock Boosted by HC Wainwright

Scholar Rock Holding Corporation (NASDAQ:SRRK) – Research analysts at HC Wainwright lifted their Q1 2026 earnings estimates for shares of Scholar Rock in a research report issued to clients and investors on Tuesday, March 3rd. HC Wainwright analyst A. Maldonado now expects that the company will earn ($0.90) per share for the quarter, up from their previous forecast of ($0.93). HC Wainwright currently has a “Buy” rating and a $58.00 target price on the stock. The consensus estimate for Scholar Rock’s current full-year earnings is ($2.42) per share. HC Wainwright also issued estimates for Scholar Rock’s Q2 2026 earnings at ($0.91) EPS, Q3 2026 earnings at ($0.92) EPS, Q4 2026 earnings at ($0.82) EPS, FY2026 earnings at ($3.55) EPS, FY2027 earnings at ($2.13) EPS, FY2028 earnings at ($0.73) EPS and FY2029 earnings at $0.33 EPS.

Other research analysts also recently issued research reports about the stock. Piper Sandler lifted their target price on shares of Scholar Rock from $51.00 to $58.00 and gave the stock an “overweight” rating in a report on Wednesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Scholar Rock in a research report on Thursday, January 22nd. JPMorgan Chase & Co. raised their price objective on shares of Scholar Rock from $46.00 to $47.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 18th. Citigroup upped their target price on shares of Scholar Rock from $55.00 to $58.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, Barclays raised their price target on shares of Scholar Rock from $52.00 to $53.00 and gave the stock an “overweight” rating in a research report on Tuesday. Four investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Scholar Rock currently has a consensus rating of “Buy” and a consensus price target of $54.14.

Scholar Rock Trading Down 1.9%

NASDAQ:SRRK opened at $45.29 on Friday. The company’s 50 day moving average is $45.32 and its 200-day moving average is $39.28. The company has a quick ratio of 6.30, a current ratio of 6.95 and a debt-to-equity ratio of 0.41. Scholar Rock has a 12 month low of $22.71 and a 12 month high of $49.82. The firm has a market cap of $5.20 billion, a price-to-earnings ratio of -13.20 and a beta of 0.70.

Scholar Rock (NASDAQ:SRRK) last issued its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.76) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.10. During the same period in the prior year, the company earned ($0.64) earnings per share.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of SRRK. Siren L.L.C. boosted its position in Scholar Rock by 17.0% in the 4th quarter. Siren L.L.C. now owns 10,825,013 shares of the company’s stock valued at $476,842,000 after buying an additional 1,575,008 shares during the last quarter. Wellington Management Group LLP raised its position in shares of Scholar Rock by 26.7% during the fourth quarter. Wellington Management Group LLP now owns 5,759,428 shares of the company’s stock worth $253,703,000 after acquiring an additional 1,213,541 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of Scholar Rock by 5.7% during the fourth quarter. Vanguard Group Inc. now owns 5,195,465 shares of the company’s stock valued at $228,860,000 after acquiring an additional 280,538 shares during the period. State Street Corp lifted its stake in shares of Scholar Rock by 7.2% during the fourth quarter. State Street Corp now owns 4,034,434 shares of the company’s stock valued at $177,717,000 after acquiring an additional 271,331 shares during the period. Finally, Orbis Allan Gray Ltd increased its position in Scholar Rock by 1,034.5% in the fourth quarter. Orbis Allan Gray Ltd now owns 3,428,929 shares of the company’s stock worth $151,044,000 after purchasing an additional 3,126,677 shares during the period. Institutional investors own 91.08% of the company’s stock.

Insider Activity

In other Scholar Rock news, CEO David Hallal sold 57,450 shares of the business’s stock in a transaction dated Tuesday, January 13th. The shares were sold at an average price of $42.70, for a total value of $2,453,115.00. Following the transaction, the chief executive officer directly owned 1,541,645 shares in the company, valued at $65,828,241.50. The trade was a 3.59% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Vikas Sinha sold 16,755 shares of the stock in a transaction that occurred on Tuesday, January 13th. The stock was sold at an average price of $42.70, for a total value of $715,438.50. Following the sale, the chief financial officer owned 583,245 shares in the company, valued at approximately $24,904,561.50. This trade represents a 2.79% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 208,470 shares of company stock worth $9,201,778 over the last ninety days. Corporate insiders own 13.30% of the company’s stock.

Scholar Rock News Summary

Here are the key news stories impacting Scholar Rock this week:

• Positive Sentiment: FDA & commercial progress for apitegromab creates a clear commercial pathway and longer‑term revenue upside, a material catalyst for the stock. Scholar Rock outlines 2026 apitegromab BLA resubmission and commercial launch following FDA progress
• Positive Sentiment: Recent quarterly results beat consensus (EPS of -$0.76 vs. -$0.86) and triggered a large volume spike, evidence of investor interest and potential momentum. Scholar Rock (NASDAQ:SRRK) Sees Large Volume Increase After Strong Earnings
• Positive Sentiment: HC Wainwright reaffirmed a Buy rating and a $58 price target while raising several medium‑ and long‑term EPS forecasts (FY2027–FY2030), signaling continued analyst conviction in the company’s longer‑term outlook. Scholar Rock (NASDAQ:SRRK) Earns “Buy” Rating from HC Wainwright
• Neutral Sentiment: HC Wainwright made a mix of small upward revisions to several quarterly estimates (Q1–Q3 2026) but these are modest improvements and mostly reflect modeling tweaks rather than changed guidance from the company.
• Negative Sentiment: HC Wainwright lowered FY2026 and Q4‑2026 EPS estimates (Q4 2026 from -$0.64 to -$0.82; FY2026 to -$3.55 from -$3.45), increasing near‑term uncertainty and likely contributing to selling pressure despite the long‑term upgrades.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).